Our 40-year heritage in respiratory medicines is just the beginning of our story. AstraZeneca has pushed the boundaries of science and helped millions of patients with respiratory disease. We are advancing a pipeline of inhaled and biologic treatments, drug combinations and devices, and other therapies that aim to transform disease management.

  • Daxas▼ (roflumilast) indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.

  • Duaklir▼(aclidinium/formoterol fumarate dehydrate) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

  • Symbicort (budesonide/formoterol) for asthma (100/6, 200/6 and 400/12 DPI). Symbicort® is indicated for adults, adolescents 12 years and older and children aged 6 years and older (100/6 only) for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting ß2-adrenoceptor agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ß2-adrenoceptor agonists; or patients already adequately controlled on both inhaled corticosteroids and long-acting ß2-adrenoceptor agonists.

  • Symbicort (budesonide/formoterol) for COPD (200/6, 400/12 DPI and 200/6 pMDI). Symbicort® is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with FEV1 <70% predicted normal (post-bronchodilator) and exacerbation history despite regular bronchodilator therapy.

GB-9784 - November 2017